Brimonidine is a highly selective α2-receptor blocker, successfully developed by the US Company Allergan, which is an eye medication. It can reduce intraocular pressure (IOP). Brimonidine tartrate ophthalmic solution saling in the market is brimonidine tartrate form, which is a good IOP-lowering medication for chronic open-angle glaucoma and ocular hypertension treatment of patients, but also for argons laser IOP levels.
Brimonidine tartrate ophthalmic solution has a dual mechanism of action by reducing aqueous humor production and increasing the pigment layer of liquid scleral outflow therapeutic purposes. After dropping into the eye, the effect is rapid, and it can reach the peak when using up to 2h, and the effective time can maintain 12h. Blood can only detect traces of drugs. This product has first-pass metabolism in the liver, and metabolites excreted in the urine by the kidneys. Systemic absorption and distribution are not affected, and the elderly do not need dose adjustment.
Brimonidine is a medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. This drug increases fluid draining from the eye and lowers the amount of fluid made in the eye. Brimonidine belongs to a class of drugs called alpha agonists. Brimonidine is a generic drug also sold under the brand names Mirvaso and Alphagan. This drug has been available for years. In the treatment of open-angle glaucoma and ocular hypertension, brimonidine use is common.
